Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525636 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
A Phase 1 study of X-linked Hypophosphatemia, sponsored by Kyowa Kirin Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 9
- Study locations
NCT06525636: Recruiting Phase 1 study of X-linked Hypophosphatemia, sponsored by Kyowa Kirin Co..
NCT06525636 is a Phase 1 study of X-linked Hypophosphatemia that is actively recruiting participants, run by Kyowa Kirin Co.. The registered enrollment target is 24 participants, below the 170-participant average among 5 other X-linked Hypophosphatemia trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06525636, a Phase 1 study of X-linked Hypophosphatemia, is actively recruiting participants, sponsored by Kyowa Kirin Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 9
- Study locations
Study Summary
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
Conditions Studied
Interventions
- DRUG KK8123
Study Locations (9)
Other
- Institute of Osteology and Biomechanics (IOBM) - Hamburg
- Universitaetsklinikum Wurzburg - Würzburg
- Hospital Universitario La Paz - Madrid
California
- University of California - San Francisco - San Francisco
Connecticut
- Yale Center for XLH/ Yale University School of Medicine - New Haven
Indiana
- Indiana University School of Medicine University Hospital - Indianapolis
Minnesota
- Mayo Clinic - Rochester
Tennessee
- Vanderbilt University Medical Center - Nashville
Paris
- Hoptial Bictre - Le Kremlin-Bicêtre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2028-05-10 |
| Phase | Phase 1 |
What NCT06525636 shows while recruiting
NCT06525636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 170-participant average among 5 other X-linked Hypophosphatemia trials with a reported enrollment target (86% lower).
The record links to 1 condition, with X-linked Hypophosphatemia appearing as the primary indexed condition, and to 1 intervention - of which KK8123 is the first listed.
NCT06525636 lists 9 locations in 7 states (Other, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06525636 about?
NCT06525636 is a clinical study titled "A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia". A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
What is the current status of trial NCT06525636?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-10-09. Estimated completion is 2028-05-10.
What conditions does trial NCT06525636 study?
This clinical trial studies the following conditions: X-linked Hypophosphatemia.
What interventions are being tested in trial NCT06525636?
The interventions under investigation include: KK8123 (DRUG).
Who is sponsoring clinical trial NCT06525636?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06525636 being conducted?
This trial has 9 study locations across California, Connecticut, Indiana, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-linked Hypophosphatemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
COMPLETED · Phase 1
-
Calcitriol Monotherapy for X-Linked Hypophosphatemia
ACTIVE NOT RECRUITING · Early Phase 1
-
X-linked Hypophosphatemia Disease Monitoring Program
ACTIVE NOT RECRUITING
-
Examining the Effect of Burosumab on Muscle Function
COMPLETED · Phase 4
-
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI